BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 31497844)

  • 1. Unique Sjögren's syndrome patient subsets defined by molecular features.
    James JA; Guthridge JM; Chen H; Lu R; Bourn RL; Bean K; Munroe ME; Smith M; Chakravarty E; Baer AN; Noaiseh G; Parke A; Boyle K; Keyes-Elstein L; Coca A; Utset T; Genovese MC; Pascual V; Utz PJ; Holers VM; Deane KD; Sivils KL; Aberle T; Wallace DJ; McNamara J; Franchimont N; St Clair EW
    Rheumatology (Oxford); 2020 Apr; 59(4):860-868. PubMed ID: 31497844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of interferon-λ in minor salivary glands of patients with primary Sjögren's syndrome and its synergic effect with interferon-α on salivary gland epithelial cells.
    Ha YJ; Choi YS; Kang EH; Chung JH; Cha S; Song YW; Lee YJ
    Clin Exp Rheumatol; 2018; 36 Suppl 112(3):31-40. PubMed ID: 28421993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course of cytokine upregulation in the lacrimal gland and presence of autoantibodies in a predisposed mouse model of Sjögren's Syndrome: the influence of sex hormones and genetic background.
    Czerwinski S; Mostafa S; Rowan VS; Azzarolo AM
    Exp Eye Res; 2014 Nov; 128():15-22. PubMed ID: 25218176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjögren's syndrome.
    Ogawa N; Ping L; Zhenjun L; Takada Y; Sugai S
    Arthritis Rheum; 2002 Oct; 46(10):2730-41. PubMed ID: 12384933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism in the 5' regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren's syndrome.
    Nossent JC; Lester S; Zahra D; Mackay CR; Rischmueller M
    Rheumatology (Oxford); 2008 Sep; 47(9):1311-6. PubMed ID: 18617551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Transcriptomic Profile of Monocytes from Patients With Sjögren's Syndrome Is Associated With Inflammatory Parameters and Is Mimicked by Circulating Mediators.
    Lopes AP; Bekker CPJ; Hillen MR; Blokland SLM; Hinrichs AC; Pandit A; Kruize AA; Radstake TRDJ; van Roon JAG
    Front Immunol; 2021; 12():701656. PubMed ID: 34413853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjögren's syndrome.
    Baer AN; McAdams DeMarco M; Shiboski SC; Lam MY; Challacombe S; Daniels TE; Dong Y; Greenspan JS; Kirkham BW; Lanfranchi HE; Schiødt M; Srinivasan M; Umehara H; Vivino FB; Vollenweider CF; Zhao Y; Criswell LA; Shiboski CH;
    Ann Rheum Dis; 2015 Aug; 74(8):1557-61. PubMed ID: 25735642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of Ro/SSA 60 kDa and La/SSB, but not Ro/SSA 52 kDa, mRNA and protein in minor salivary glands from patients with primary Sjögren's syndrome.
    Barcellos KS; Nonogaki S; Enokihara MM; Teixeira MS; Andrade LE
    J Rheumatol; 2007 Jun; 34(6):1283-92. PubMed ID: 17552056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A re-evaluation of anti-NA-14 antibodies in patients with primary Sjögren's syndrome: Significant role of interferon-γ in the production of autoantibodies against NA-14.
    Uomori K; Nozawa K; Ikeda K; Doe K; Yamada Y; Yamaguchi A; Fujishiro M; Kawasaki M; Morimoto S; Takamori K; Sekigawa I; Chan EK; Takasaki Y
    Autoimmunity; 2016 Aug; 49(5):347-56. PubMed ID: 27328271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of BAFF and IL-17A with subphenotypes of primary Sjögren's syndrome.
    Deng F; Chen J; Zheng J; Chen Y; Huang R; Yin J; Gao X; Lin Q; Huang C; Gao Y; Yu X; Liu Z
    Int J Rheum Dis; 2016 Jul; 19(7):715-20. PubMed ID: 25941062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmacytoid DCs From Patients With Sjögren's Syndrome Are Transcriptionally Primed for Enhanced Pro-inflammatory Cytokine Production.
    Hillen MR; Pandit A; Blokland SLM; Hartgring SAY; Bekker CPJ; van der Heijden EHM; Servaas NH; Rossato M; Kruize AA; van Roon JAG; Radstake TRDJ
    Front Immunol; 2019; 10():2096. PubMed ID: 31552042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Ro/SSA and anti-La/SSB autoantibodies in the tear fluid of patients with Sjögren's syndrome.
    Toker E; Yavuz S; Direskeneli H
    Br J Ophthalmol; 2004 Mar; 88(3):384-7. PubMed ID: 14977774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the anti-Ro/SSA autoantibody profile between patients with primary and secondary Sjögren's syndrome.
    Gál I; Lakos G; Zeher M
    Autoimmunity; 2000 Sep; 32(2):89-92. PubMed ID: 11078154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural Killer Cell Transcript 4 promotes the development of Sjӧgren's syndrome via activation of Rap1 on B cells.
    Qu P; Wuest T; Min Y; Alevizos I; Young HA; Lin PC
    J Autoimmun; 2021 Jan; 116():102559. PubMed ID: 33087256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive review of autoantibodies in primary Sjögren's syndrome: clinical phenotypes and regulatory mechanisms.
    Kyriakidis NC; Kapsogeorgou EK; Tzioufas AG
    J Autoimmun; 2014 Jun; 51():67-74. PubMed ID: 24333103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokine saliva levels in patients with primary Sjögren's syndrome, associated Sjögren's syndrome, pre-clinical Sjögren's syndrome and systemic autoimmune diseases.
    Hernández-Molina G; Michel-Peregrina M; Hernández-Ramírez DF; Sánchez-Guerrero J; Llorente L
    Rheumatology (Oxford); 2011 Jul; 50(7):1288-92. PubMed ID: 21330342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjögren's syndrome (pSS): a European multicentre study.
    Tzioufas AG; Wassmuth R; Dafni UG; Guialis A; Haga HJ; Isenberg DA; Jonsson R; Kalden JR; Kiener H; Sakarellos C; Smolen JS; Sutcliffe N; Vitali C; Yiannaki E; Moutsopoulos HM
    Ann Rheum Dis; 2002 May; 61(5):398-404. PubMed ID: 11959762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased circulating CXCR3 + CCR9+T helper cells are associated with elevated levels of their ligands CXCL10 and CCL25 in the salivary gland of patients with Sjögren's syndrome to facilitate their concerted migration.
    Blokland SLM; Kislat A; Homey B; Smithson GM; Kruize AA; Radstake TRDJ; van Roon JAG
    Scand J Immunol; 2020 Mar; 91(3):e12852. PubMed ID: 31733111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response.
    Gottenberg JE; Busson M; Loiseau P; Cohen-Solal J; Lepage V; Charron D; Sibilia J; Mariette X
    Arthritis Rheum; 2003 Aug; 48(8):2240-5. PubMed ID: 12905478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic role of endogenous TNF-α in the development of Sjögren's-like sialadenitis and secretory dysfunction in non-obese diabetic mice.
    Zhou J; Kawai T; Yu Q
    Lab Invest; 2017 Apr; 97(4):458-467. PubMed ID: 28067896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.